New Retina Radio by Eyetube - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

New Retina Radio by Eyetube — Science
New Retina Radio by Eyetube

New Retina Radio is a place to hear stories about retina that are told nowhere else.

Copyright: © 2020 Bryn Mawr Communications LLC

Latest Episodes:

Fluid in Neovascular Age-Related Macular Degeneration – Evolution of Understanding Jan 20, 2021

Show notes

Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the HARBOR and FLUID clinical trials and the Fight Retinal Blindness! project, and consider key questions such as whether fluid can be protective and which types of fluid need to be treated aggressively.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Imaging Modalities in DR Jan 08, 2021

Show notes

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Intravitreal Dexamethasone Implant in DME Patients Dec 21, 2020

Show notes

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report.

This editorially independent podcast is supported with advertising.

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier Dec 17, 2020

Show notes

How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.

This editorially independent podcast is supported with advertising.

DRCR Retina Network Protocol AB at AAO Dec 07, 2020

Show notes

DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: IRIS Registry Data on GA Dec 02, 2020

Show notes

Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

Coding Changes for 2021 at AAO Nov 30, 2020

Show notes

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: Ang-2 Mediation in DME Therapy Nov 25, 2020

Show notes

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

Retinal Arteriolar Macroaneurysm and Anti-VEGF Therapy at AAO Nov 23, 2020

Show notes

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: KSI-301 in DME Therapy Nov 20, 2020

Show notes

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

Related Podcasts